Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.40 |
| ▸ | PDE8B | O95263 | 1/20 | 0.40 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124328 | 0.83 | METTL3 (0.49) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL7860235 | 0.81 | METTL3 (0.43) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL2123536 | 0.77 | METTL3 (0.48) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL2512520 | 0.77 | PDE8B (0.42) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL7787688 | 0.77 | KCNK3 (0.44) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL2120886 | 0.76 | PDE8B (0.41) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL86137 | 0.75 | PDE8B (0.42) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL12225863 | 0.74 | PDE8B (0.43) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL2121708 | 0.73 | METTL3 (0.54) | KDM1AHCRTR2PDE8BMETTL3PRMT5 | |
| SCHEMBL30740781 | 0.72 | KDM1A (0.44) | KDM1AHCRTR2PDE8BMETTL3PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267730-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267730-A1 | NOVEL COMPOUNDS | BRD4, DPP4, ITPR3 | KDM1A 3997/4885HCRTR2 1658/4885PDE8B 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.